The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
GLI1 regulates a novel neuropilin‐2/α6β1 integrin based autocrine pathway that contributes to breast cancer initiation
Open accessAbstract
The characterization of cells with tumour initiating potential is significant for advancing our understanding of cancer and improving therapy. Aggressive, triple-negative breast cancers (TNBCs) are enriched for tumour-initiating cells (TICs). We investigated that hypothesis that VEGF receptors expressed on TNBC cells mediate autocrine signalling that contributes to tumour initiation. We discovered the VEGF receptor neuropilin-2 (NRP2) is expressed preferentially on TICs, involved in the genesis of TNBCs and necessary for tumour initiation. The mechanism by which NRP2 signalling promotes tumour initiation involves stimulation of the α6β1 integrin, focal adhesion kinase-mediated activation of Ras/MEK signalling and consequent expression of the Hedgehog effector GLI1. GLI1 also induces BMI-1, a key stem cell factor, and it enhances NRP2 expression and the function of α6β1, establishing an autocrine loop. NRP2 can be targeted in vivo to retard tumour initiation. These findings reveal a novel autocrine pathway involving VEGF/NRP2, α6β1 and GLI1 that contributes to the initiation of TNBC. They also support the feasibility of NRP2-based therapy for the treatment of TNBC that targets and impedes the function of TICs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302
Glinsky, G. V., Berezovska, O., & Glinskii, A. B. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23412 · Cited by 916 · cited 1×
“A critical feature of GLI1 in this context is its ability to induce BMI-1, a transcriptional repressor that has been implicated in the function of mammary tumour stem cells (Glinsky et al, 2005; Liu et al, 2006).”
Cited by
Goel, H. L., & Mercurio, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3627 · Cited by 1,253
Self-citationCooper, J., & Giancotti, F. G. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.007 · Cited by 945
Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance
Seguin, L., Desgrosellier, J. S., Weis, S. M., & Cheresh, D. A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.12.006 · Cited by 685
The Role of the Extracellular Matrix in Cancer Stemness
Nallanthighal, S., Heiserman, J. P., & Cheon, D.-J. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00086 · Cited by 344
VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2
Zhao, D., Pan, C., Sun, J., Gilbert, C., Drews-Elger, K., Azzam, D. J., Picon-Ruiz, M., Kim, M., Ullmer, W., El-Ashry, D., et al. (2015) · Oncogene · doi:10.1038/onc.2014.257 · Cited by 267
The impact of Mesenchymal Stem Cells and their secretome as a treatment for gliomas
Gomes, E. D., Vieira de Castro, J., Costa, B. M., & Salgado, A. J. (2018) · Biochimie · doi:10.1016/j.biochi.2018.07.008 · Cited by 28
Metadata
- Authors
- Goel, H. L., Pursell, B., Chang, C., Shaw, L. M., Mao, J., Simin, K., Kumar, P., Kooi, C. W. V., Shultz, L. D., Greiner, D. L., Norum, J. H., Toftgard, R., Kuperwasser, C., & Mercurio, A. M.
- Venue
- EMBO Molecular Medicine
- Published
- 2013-02-21
- Volume
- 5
- Issue
- 4
- Pages
- 488-508
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2161037680
- Cited by
- 167
- References
- 3
- FWCI
- 7.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.